Abstract: The present invention relates to regulation of IgE-receptor-mediated mast cell degranulation. More particularly, the present invention is directed to nucleic acids encoding CD43 (also called leukosialin or leukocyte large sialoglycoprotein), which is involved in modulation of IgE-receptor-mediated mast cell degranulation. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, siRNA, antisense nucleic acids, and ribozymes, that modulate IgE-receptor-mediated mast cell degranulation via modulation of CD43 and CD43-related signal transduction; as well as to the use of expression profiles and compositions in diagnosis and therapy related to diseases such as allergies and asthma.
Type:
Application
Filed:
May 31, 2002
Publication date:
February 6, 2003
Applicant:
Rigel Pharmaceuticals, Incorporated
Inventors:
Mark Bennett, Sacha Holland, Alex Rossi
Abstract: The present invention relates to regulation of T cell activation. More particularly, the present invention is directed to nucleic acids encoding alpha 2 integrin. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, siRNA, antisense nucleic acids, and ribozymes, that modulate T cell activation via modulation of alpha 2 integrin and alpha 2 integrin-related signal transduction; as well as to the use of expression profiles and compositions in diagnosis and therapy related to autoimmune disease and tissue and organ transplant.
Type:
Application
Filed:
May 30, 2002
Publication date:
January 16, 2003
Applicant:
Rigel Pharmaceuticals, Incorporated
Inventors:
Peter Chu, Congfen Li, X. Charlene Liao, Jorge Pardo
Abstract: The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding C1-angiogenesis protein, also called integrin-linked kinase associated protein (“ILKAP”) and ILKAP protein, which is involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, and ribozymes, that modulate angiogenesis via modulation of ILKAP and ILKAP-related cascades; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis.
Type:
Application
Filed:
August 21, 2001
Publication date:
October 24, 2002
Applicant:
Rigel Pharmaceuticals, Incorporated
Inventors:
James B. Lorens, Weiduan Xu, Robert E. Atchison, Jakob Bogenberger